Despite considerable success in treatment of early stage localized prostate cancer (PC),
acute inadequacy of late stage PC treatment and its inherent heterogeneity poses a …

Macrophage inhibitory cytokine-1 (MIC-1/GDF15), a divergent member of the TGF-β
superfamily, is over-expressed by many common cancers including those of the prostate …

Background Several lines of evidence suggest effects of dietary fat on prostate cancer (PCa)
development and progression. Targeting omega (ω)‐3: ω6 fatty acids (FA) ratio could be …

It has previously been shown that curcumin can effectively inhibit prostate cancer
proliferation and progression in TRAMP mice, potentially acting through the hypomethylation …

Genetically modified hematopoietic progenitors represent an important testing platform for a
variety of cell-based therapies, pharmaceuticals, diagnostics and other applications. Stable …

Although androgen deprivation therapy (ADT) and immunotherapy are potential treatment
options in men with metastatic prostate cancer (CaP), androgen has conventionally been …

Bone morphogenetic protein (BMP) is a pleiotropic growth factor that has been implicated in
inflammation and prostate cancer (CaP) progression. We investigated the potential role of …

Onco-immunotherapy via blocking checkpoint-inhibitors has revolutionized the treatment-
landscape of several malignancies, though not in the metastatic castration-resistant prostate …

Surfactant protein D (SP-D), a pattern recognition molecule, is emerging as a potent anti-
tumoural innate immune defense molecule in a range of cancers. Previously, SP-D …

The goals of any cancer therapy are to improve disease control, palliate pain and improve
overall survival. We are fortunate to have in our cancer armamentarium two new immune …